SR One | Activity | F4

Introducing F4 Champions, a new accelerator for founders at the earliest stage.F4 Champions for early-stage foundersEnrollment closesAugust 2Learn more

Team Portfolio Raise Champions Essays

F4/SR One/Activity

SR One Activity

Every public signal F4 has attached to this firm, with sources and cross-entity links.

Types

Time range

Investment

Crystalys Therapeutics closed a $130M Series B to advance Phase 3 development of dotinurad for gout.

Crystalys Therapeutics

Crystalys Therapeutics SR One

prnewswire.comJUL 22, 2026

JUL 22, 2026

Exit

Ipsen announced its acquisition of portfolio company Kartos Therapeutics to expand its hemato-oncology pipeline.

Kartos Therapeutics

Kartos TherapeuticsSR One

ipsen.comJUN 29, 2026

JUN 29, 2026

Milestone

Odyssey Therapeutics priced an upsized initial public offering.

Odyssey Therapeutics

Odyssey Therapeutics SR One

investors.odysseytx.comMAY 7, 2026

MAY 7, 2026

Investment

Windward Bio closed a $165M crossover financing to advance long-acting immunology therapies.

Windward Bio

Windward Bio SR One

globenewswire.comMAY 4, 2026

MAY 4, 2026

Milestone

Avalyn priced an upsized initial public offering.

Avalyn Pharma

Avalyn PharmaSR One

investors.avalynpharma.comAPR 29, 2026

APR 29, 2026

Investment

Immutrin raised a £65M ($87M) Series A to develop an antibody therapy for ATTR amyloidosis.

Immutrin

ImmutrinSR One

globenewswire.comMAR 24, 2026

MAR 24, 2026

Investment

Poplar Therapeutics closed a $45M Series A extension to advance its anti-IgE therapy.

Poplar Therapeutics

Poplar TherapeuticsSR One

businesswire.comMAR 4, 2026

MAR 4, 2026

Exit

Gilead announced its acquisition of portfolio company Arcellx to advance anito-cel.

Arcellx

Arcellx SR One

gilead.comFEB 23, 2026

FEB 23, 2026

Milestone

Veradermics priced an upsized initial public offering.

Veradermics

Veradermics SR One

ir.veradermics.comFEB 4, 2026

FEB 4, 2026

4 investments· DEC 2025 – JAN 2026Show all

Investment

Corxel closed a $287M Series D1 financing to advance its cardiometabolic pipeline including an oral GLP-1 receptor agonist.

Corxel Pharmaceuticals

Corxel PharmaceuticalsSR One

corxelbio.comJAN 22, 2026

JAN 22, 2026

Investment

AirNexis Therapeutics launched with a $200M Series A to advance its dual PDE3/4 inhibitor for COPD.

AirNexis Therapeutics

AirNexis Therapeutics SR One

businesswire.comJAN 9, 2026

JAN 9, 2026

Investment

Poplar Therapeutics launched with a $50M Series A to advance a new class of anti-IgE therapy.

Poplar Therapeutics

Poplar TherapeuticsSR One

businesswire.comJAN 7, 2026

JAN 7, 2026

Investment

Addition Therapeutics announced $100M in funding to advance genomic medicine for chronic and rare diseases.

Addition Therapeutics

Addition TherapeuticsSR One

additiontx.comDEC 17, 2025

DEC 17, 2025

Exit

Renalys Pharma announced it will be acquired by Chugai Pharmaceutical.

Renalys Pharma

Renalys PharmaSR One

prnewswire.comOCT 24, 2025

OCT 24, 2025

Page 1 of 2